peoplePerson
Helena A. Yu
Mapped how EGFR-mutant lung cancers resist osimertinib and led the HER3-directed ADC trials that followed.
Characterised acquired resistance mechanisms to EGFR inhibitors, including T790M and histologic transformation, and was a principal investigator of the HERTHENA-Lung01 patritumab deruxtecan study.
Role
Medical Oncologist, Thoracic Oncology Service
Institution
Specialisms
EGFR-mutant lung cancerResistance mechanismsADCs in lung cancer
Profiles
| Title | Journal | Year |
|---|---|---|
| Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers | Clinical Cancer Research | 2013 |
| HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC after EGFR TKI therapy and platinum-based chemotherapy | Journal of Clinical Oncology | 2023 |